NASDAQ: CADLCandel Therapeutics Inc Stock
$4.91+0.07 (+1.45%)
Updated Apr 30, 2025
CADL Price
$4.91
Fair Value Price
$2.90
Market Cap
$231.93M
52 Week Low
$3.79
52 Week High
$14.60
P/E
-2.82x
P/B
3.5x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$55.18M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.61
Operating Cash Flow
-$27M
Beta
1.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CADL Overview
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer patients. Its pipeline includes CAN-2409, in Phase II clinical trials for the treatment of pancreatic cancer, Phase III clinical trials for the treatment of prostate cancer, Phase II clinical trials for the treatment of lung cancer, and Phase Ib/II clinical trials (completed) for the treatment of high-grade glioma. The company is also developing CAN-3110, in Phase I clinical trials for the treatment of recurrent glioblastoma. Candel Therapeutics was incorporated in 2003 and is based in Needham, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CADL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CADL
Ranked#369 of 462
Ranked#369 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important CADL news, forecast changes, insider trades & much more!
CADL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CADL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CADL ($4.91) is overvalued by 69.44% relative to our estimate of its Fair Value price of $2.90 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CADL ($4.91) is not significantly undervalued (69.44%) relative to our estimate of its Fair Value price of $2.90 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CADL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CADL due diligence checks available for Premium users.
Valuation
CADL fair value
Fair Value of CADL stock based on Discounted Cash Flow (DCF)
Price
$4.91
Fair Value
$2.90
Overvalued by
69.44%
CADL ($4.91) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CADL ($4.91) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CADL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CADL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.82x
Industry
-162.28x
Market
29.18x
CADL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.5x
Industry
4.45x
CADL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CADL's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.1M
Profit Margin
0%
CADL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$106.9M
Liabilities
$40.5M
Debt to equity
0.61
CADL's short-term assets ($103.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CADL's short-term assets ($103.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CADL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CADL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.8M
Investing
-$3.0k
Financing
$91.9M
CADL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CADL vs Biotech Stocks
Candel Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.